Sarepta Therapeutics, Inc.
SRPT
$18.84
-$0.29-1.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 330.96M | -282.85M | -179.95M | 196.89M | -447.51M |
| Total Depreciation and Amortization | 10.59M | 5.25M | 18.45M | 10.84M | 9.98M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.02M | 69.29M | 176.14M | 4.07M | 135.87M |
| Change in Net Operating Assets | -586.25M | 339.51M | -29.23M | 49.53M | -281.78M |
| Cash from Operations | -202.68M | 131.21M | -14.59M | 261.34M | -583.44M |
| Capital Expenditure | -2.08M | -3.59M | -22.93M | -31.80M | -43.65M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -132.31M | 99.80M | 255.33M | 64.01M | -247.53M |
| Cash from Investing | -134.39M | 96.21M | 232.40M | 32.21M | -291.18M |
| Total Debt Issued | 250.00M | -- | -- | -- | -- |
| Total Debt Repaid | -250.00M | -35.13M | -123.94M | -304.00K | -3.21M |
| Issuance of Common Stock | 241.00K | 308.00K | 21.21M | 1.50M | 15.68M |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | -25.01M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -4.38M | -15.06M | -- | -- |
| Cash from Financing | 241.00K | -39.21M | -117.79M | -23.82M | 12.47M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -336.83M | 188.21M | 100.03M | 269.73M | -862.14M |